Diminished phosphodiesterase-8B potentiates biphasic insulin response to glucose

被引:38
作者
Dov, Avital [1 ]
Abramovitch, Eva [1 ]
Warwar, Nasim [1 ]
Nesher, Rafael [1 ]
机构
[1] Hebrew Univ Jerusalem, Med Ctr, Dept Med, Endocrinol & Metab Serv, IL-91120 Jerusalem, Israel
关键词
D O I
10.1210/en.2007-0968
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
cAMP activates multiple signal pathways, crucial for the pancreatic beta-cells function and survival and is a major potentiator of insulin release. A family of phosphodiesterases (PDEs) terminate the cAMP signals. We examined the expression of PDEs in rat beta-cells and their role in the regulation of insulin response. Using RT-PCR and Western blot analyses, we identified PDE3A, PDE3B, PDE4B, PDE4D, and PDE8B in rat islets and in INS-1E cells and several possible splice variants of these PDEs. Specific depletion of PDE3A with small interfering (si) RNA (siPDE3A) led to a small (67%) increase in the insulin response to glucose in INS-1E cells but not rat islets. siPDE3A had no effect on the glucagon-like peptide-1 (10 nmol/ liter) potentiated insulin response in rat islets. Depletion in PDE8B levels in rat islets using similar technology (siPDE8B) increased insulin response to glucose by 70%, the potentiation being of similar magnitude during the first and second phase insulin release. The siPDE8B-potentiated insulin response was further increased by 23% when glucagon-like peptide-1 was included during the glucose stimulus. In conclusion, PDE8B is expressed in a small number of tissues unrelated to glucose or fat metabolism. We propose that PDE8B, an 3-isobutyl-1-methylxanthine-insensitive cAMP-specific phosphodiesterase, could prove a novel target for enhanced insulin response, affecting a specific pool of cAMP involved in the control of insulin granule trafficking and exocytosis. Finally, we discuss evidence for functional compartmentation of cAMP in pancreatic beta-cells.
引用
收藏
页码:741 / 748
页数:8
相关论文
共 47 条
[1]   GLP-1 based therapy for type 2 diabetes [J].
Arulmozhi, DK ;
Portha, B .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2006, 28 (1-2) :96-108
[2]   A-kinase anchoring proteins take shape [J].
Beene, Darren L. ;
Scott, John D. .
CURRENT OPINION IN CELL BIOLOGY, 2007, 19 (02) :192-198
[3]   Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus [J].
Briones, Mariele ;
Bajaj, Mandeep .
EXPERT OPINION ON PHARMACOTHERAPY, 2006, 7 (08) :1055-1064
[4]   How do different GLP-1 mimetics differ in their actions? [J].
Choukem S.P. ;
Gautier J.-F. .
Current Diabetes Reports, 2006, 6 (5) :365-372
[5]   GLP-1 and type 2 diabetes: physiology and new clinical advances [J].
Combettes, Murielle M. J. .
CURRENT OPINION IN PHARMACOLOGY, 2006, 6 (06) :598-605
[6]   Compartmentalization of adenylate cyclase and cAMP signalling [J].
Cooper, DMF .
BIOCHEMICAL SOCIETY TRANSACTIONS, 2005, 33 :1319-1322
[7]   Cooperative effects between protein kinase A and p44/p42 mitogen-activated protein kinase to promote cAMP-responsive element binding protein activation after β cell stimulation by glucose and its alteration due to glucotoxicity [J].
Costes, S ;
Longuet, C ;
Broca, C ;
Faruque, O ;
Hani, EH ;
Bataille, D ;
Dalle, S .
SIGNAL TRANSDUCTION PATHWAYS, CHROMATIN STRUCTURE, AND GENE EXPRESSION MECHANISMS AS THERAPEUTIC TARGETS, 2004, 1030 :230-242
[8]   Metabolic control of β-cell function [J].
Deeney, JT ;
Prentki, M ;
Corkey, BE .
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY, 2000, 11 (04) :267-275
[9]   Forskolin suppresses insulin gene transcription in islet β-cells through a protein kinase A-independent pathway [J].
Ding, WQ ;
Dong, MQ ;
Ninova, D ;
Holicky, EL ;
Stegall, MD ;
Miller, LJ .
CELLULAR SIGNALLING, 2003, 15 (01) :27-35
[10]   Pharmacological agents that directly modulate insulin secretion [J].
Doyle, ME ;
Egan, JM .
PHARMACOLOGICAL REVIEWS, 2003, 55 (01) :105-131